2391. Evaluation and Adjudication of Case Reports of Myocarditis After mRNA-1273 Vaccination

BACKGROUND: Myocarditis and/or pericarditis have been identified as very rare adverse events (AEs) associated with administration of COVID-19 vaccines, particularly mRNA vaccines. Cases were disproportionately reported in young men aged 18-24 years, within a few days after vaccination, mostly following a second dose. This analysis describes findings of the evaluation and adjudication of myocarditis/pericarditis AE reports (18 Dec 2020 – 17 Dec 2022) in the Moderna Global Safety Database (GSDB) following mRNA-1273 vaccination. METHODS: Two different case definitions were used to characterize level of diagnostic certainty and identify strength of evidence supporting a diagnosis of myocarditis/pericarditis: the Brighton Collaboration (BC) Case Definition (1-5 categories) and the Centers for Disease Control and Prevention (CDC) definition (probable/confirmed). Causality assessment was conducted using the standard WHO-UMC criteria. Based on epidemiological criteria, analysis was concentrated on reported cases involving individuals aged <40 years, including < 18 years, after >2 doses of mRNA-1273 and bivalent vaccines, regardless of the time-to-onset of AEs after vaccination. RESULTS: There were 6702 myocarditis/pericarditis cases after an estimated 773 million doses of mRNA-1273 (monovalent) or bivalent vaccine administered during the analysis period. There were no significant temporal changes in the demographic distribution of reported cases; 66.2% of these cases occurred in men aged 18-39 years (Figure 1) and after the second dose (28.3%). In individuals < 40 years of age, according to the BC, 38.1% of the cases were confirmed/probable; according to CDC definition 37% of the cases were confirmed/probable. WHO causality assessment indicated that 39.8% of the cases were probable/possible. Figure 1 [Figure: see text] Percentage of mRNA-1273, mRNA-1273.214 (Original/BA.1) and mRNA-1273.222 (Original/ BA.4/5) Reported Cases of Myocarditis and Pericarditis by Age and Sex (18 December 2022 to 17 December 2022) CONCLUSION: Adjudication of myocarditis/pericarditis cases following mRNA-1273 indicated that where information was available, most reports were Probable Cases, for both BC and CDC case definitions. According to WHO-UMC causality assessment most cases were considered possibly related to mRNA-1273. DISCLOSURES: Veronica Urdaneta, MD, MPH, Moderna, Inc.: Salary|Moderna, Inc.: Stocks/Bonds Priyadarshani Dharia, PhD, MD, MPH, Moderna, Inc.: Salary|Moderna, Inc.: Stocks/Bonds Oketoun Akangbe, PharmD, Moderna, Inc.: Salary|Moderna, Inc.: Stocks/Bonds Samantha St Laurent, MPH, Moderna, Inc.: Salary|Moderna, Inc.: Stocks/Bonds Daina Esposito, PhD, MPH, Moderna, Inc.: Salary|Moderna, Inc.: Stocks/Bonds Magalie Emile-Backer, PharmD, CCRP, Moderna, Inc.: Salary|Moderna, Inc.: Stocks/Bonds Walter Straus, MD, MPH, Moderna, Inc.: Salary|Moderna, Inc.: Stocks/Bonds